# Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

> **NCT02492711** · PHASE3 · COMPLETED · sponsor: **MacroGenics** · enrollment: 624 (actual)

## Conditions studied

- HER-2 Positive Breast Cancer
- Metastatic Neoplasm

## Interventions

- **BIOLOGICAL:** Margetuximab
- **BIOLOGICAL:** Trastuzumab
- **DRUG:** Physician's choice of chemotherapy.

## Key facts

- **NCT ID:** NCT02492711
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-24
- **Primary completion:** 2021-08-11
- **Final completion:** 2022-06-14
- **Target enrollment:** 624 (ACTUAL)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02492711

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02492711, "Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02492711. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*